Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.79 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.79 |
| ▸ | PTGIR | P43119 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HK1 | P19367 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558834 | 0.92 | PTGDR2 (0.82) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| Timapiprant SCHEMBL1782956 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| Timapiprant SCHEMBL29648518 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| Timapiprant SCHEMBL29379400 | 0.88 | PTGDR2 (1.00) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL22167497 | 0.86 | PTGDR2 (0.80) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL14658903 | 0.85 | PTGDR2 (0.76) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL27978015 | 0.84 | PTGDR2 (0.72) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL13640287 | 0.83 | PTGDR2 (0.73) | PTGDR2PTGDRPTGIRCYP1A2CYP3A4 | |
| SCHEMBL2670064 | 0.82 | PTGDR2 (0.62) | PTGDR2PTGDRPTGIRALDH1A1HK1 | |
| SCHEMBL15046163 | 0.81 | PTGDR2 (0.52) | PTGDR2PTGDRPTGIRALDH1A1HK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345897-A1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345897-A1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2018-07-11 | — | — | EP | disclosed |
| EP-2697215-B1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| EP-2697215-B1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| EP-2791129-B1 | PROCESS FOR THE PREPARATION OF (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2791129-B1 | PROCESS FOR THE PREPARATION OF (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID ESTERS | ATOPIX THERAPEUTICS LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-9102658-B2 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102658-B2 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102658-B2 | Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-8980918-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-20100056544-A1 | Salts with CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100041699-A1 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID | OXAGEN LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-20100041699-A1 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID | OXAGEN LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| CN-101432264-A | Salts with CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-05-13 | — | — | CN | disclosed |
| EP-2004602-A1 | SALTS WITH CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2008-12-24 | — | — | EP | disclosed |
| CN-101133047-A | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid | OXAGEN LTD (GB) | 2008-02-27 | — | — | CN | disclosed |
| EP-1856094-A1 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)ACETIC ACID | Oxagen Limited (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007107772-A1 | SALTS WITH CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107772-A1 | SALTS WITH CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006092579-A1 | MICROCRYSTALLINE ( 5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID | OXAGEN LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056544-A1 | Salts with CRTH2 Antagonist Activity | KCNH2, KCNH1, KCNH3 | PTGDR2 80/4885PTGDR 147/4885PTGIR 561/4885 |
| US-20100041699-A1 | MICROCRYSTALLINE (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL) ACETIC ACID | HRH2, GRK2, GRK5 | PTGDR2 6/4885PTGDR 20/4885PTGIR 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.